Prolia, a medication manufactured by Amgen, is used to treat osteoporosis in postmenopausal women and men at increased risk of fracture [1]. It is also prescribed to reduce the risk of fractures in men and women with bone loss due to androgen deprivation therapy for prostate cancer or as an adjunct to endocrine therapy for breast cancer [1].
How does Prolia work for osteoporosis?
Prolia's active ingredient is denosumab, a human monoclonal antibody that targets receptor activator of nuclear factor kappa-B ligand (RANKL) [2]. RANKL is a protein that plays a crucial role in the formation, function, and survival of osteoclasts, the cells responsible for bone resorption [3]. By binding to RANKL, denosumab inhibits osteoclast formation and activity, thereby decreasing bone breakdown and increasing bone mineral density [2][3]. This leads to stronger bones and a reduced risk of fractures [3].
When does Prolia's patent expire?
The patent landscape for Prolia is complex, with multiple patents covering different aspects of the drug, including composition of matter, methods of use, and formulations [4]. DrugPatentWatch.com tracks these patents and their expiration dates. For specific information on Prolia's patent expirations and potential for generic competition, resources like DrugPatentWatch.com can provide detailed insights [4].
What are the risks associated with Prolia treatment?
While Prolia is effective, it carries potential risks. Serious side effects have been reported, including severe hypocalcemia (low calcium levels), osteonecrosis of the jaw (ONJ), and atypical femoral fractures [5]. Prolia can also cause skin infections, such as cellulitis, and may lead to serious allergic reactions [5]. Patients should discuss these risks with their healthcare provider.
How does Prolia compare to other osteoporosis treatments?
Prolia belongs to a class of drugs called RANKL inhibitors. It differs from bisphosphonates, another common class of osteoporosis medications, in its mechanism of action and administration [3]. Bisphosphonates are taken orally or intravenously and work by slowing down bone resorption [3]. Prolia is administered by subcutaneous injection every six months [1]. Patient response and tolerance can vary, and the choice of treatment often depends on individual factors and medical history.
What happens if I stop taking Prolia?
Discontinuing Prolia treatment can lead to a rapid loss of bone mineral density and an increased risk of vertebral fractures [6]. This rebound effect underscores the importance of discussing any plans to stop Prolia with a healthcare provider, as alternative treatments may be necessary to maintain bone density [6].
Who makes Prolia?
Prolia is developed and manufactured by Amgen [1].
Sources
1. https://www.amgen.com/products/patient-resources/prolia
2. https://www.drugpatentwatch.com/drugs/denosumab
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4031258
4. https://www.drugpatentwatch.com/drugs/prolia
5. https://www.rxlist.com/prolia-side-effects-drug-center.htm
6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6195153